OBSV ObsEva SA

13.38
+0.51  (+4%)
Previous Close 12.87
Open 12.95
Price To Book 3.96
Market Cap 581279529
Shares 43,443,911
Volume 61,143
Short Ratio
Av. Daily Volume 58,172

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 4Q 2019.
OBE2109 - PRIMROSE 2
Uterine fibroids
Phase 2a Part B interim analysis due 1H 2019.
OBE022 - PROLONG
Pre-term labor
Phase 3 data released February 26,2018 - primary endpoint met. Improvement shown in ET D5 subgroup but not in ET D3. Further data due 2Q 2019.
OBE001 - IMPLANT2
IVF
Phase 3 data due early 2020.
OBE2109 - PRIMROSE
Uterine fibroids
Phase 2b 48 and 52-week data due 1H 2019.
OBE2109
Endometriosis
Phase 3 data due 4Q 2019.
Nolasiban (OBE001) - IMPLANT 4
Improving IVF outcomes

Latest News

  1. ObsEva SA to Participate in Upcoming Investor Conferences
  2. Publication of ObsEva SA Invitation to 2019 Annual General Meeting of Shareholders
  3. Edited Transcript of OBSV.O earnings conference call or presentation 5-Mar-19 1:00pm GMT
  4. ObsEva SA to Present OBE022 Clinical Data for Treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019
  5. ObsEva SA (OBSV) Q4 2018 Earnings Conference Call Transcript
  6. ObsEva Reports Fourth Quarter and Full Year 2018 Financial Results, Provides Business Update
  7. ObsEva SA to Hold Fourth Quarter and Full Year 2018 Financial Results and Business Update Call on March 5, 2019
  8. Are ObsEva SA’s (NASDAQ:OBSV) Interest Costs Too High?
  9. ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG Trial
  10. ObsEva SA to Participate in JP Morgan Healthcare Conference January 7-10, 2019
  11. Hedge Funds Are Betting On ObsEva SA (OBSV)
  12. ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 2 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids
  13. What Kind Of Investor Owns Most Of ObsEva SA (NASDAQ:OBSV)?
  14. ObsEva R&D Day Showcases Multiple Women’s Health Programs and Outlines Plans for Transition to Commercial Operations
  15. ObsEva SA to Participate in BMO Healthcare Conference December 12, 2018
  16. ObsEva SA to Host R&D Investor Day December 7, 2018
  17. ObsEva SA Announces Initiation of Phase 3 IMPLANT 4 Trial of Nolasiban in Europe, Canada and Russia for Improving IVF Outcomes
  18. Edited Transcript of OBSV.O earnings conference call or presentation 8-Nov-18 1:00pm GMT
  19. ObsEva SA (OBSV) Reports Q3 Loss, Misses Revenue Estimates